Regentis Biomaterials, an Israeli regenerative medicine company developing orthopedic hydrogel implants, filed on Tuesday with the SEC to raise up to $10 million in an initial public offering.
The Herzliya, Israel-based company plans to raise $10 million by offering 0.9 million shares at a price range of $10 to $12. At the midpoint of the proposed range, Regentis Biomaterials would command a fully diluted market value of $61 million.
Regentis is a regenerative medicine company focused on developing orthopedic treatments using its Gelrin platform, based on degradable hydrogel implants to regenerate damaged or diseased tissue. Its lead candidate is GelrinC, a cell-free, off-the-shelf hydrogel that is cured into an implant in the knee for the treatment of painful injuries to articular knee cartilage. GelrinC was approved as a device in Europe in 2017, and the company plans to identify strategic partners in Europe to bring the product to market. To obtain marketing approval in the US, Regentis is currently carrying out a pivotal trial for pre-marketing approval. The trial was initiated in late 2017, and the company expects to complete patient recruitment by the end of 2025.
Regentis Biomaterials was founded in 2004 and plans to list on the Nasdaq under the symbol RGNT. The company filed confidentially on January 24, 2025. ThinkEquity is the sole bookrunner on the deal.
